| |
| Plus: ICYMI from Patient Care® Online |
| |
|
Highlights of FDA Approvals for Q3 2019 |
Q3 approvals include the first oral GLP-1 RA inhibitor, 2 novel glucagon formulations, an app-linked asthma inhaler, and 6 more of interest to primary care.
Read more
|
| |
|
"Brain Pacemaker" Shows Promise for Treatment-Resistant Depression |
A new study suggests that deep brain stimulation may be a safe and effective treatment option for patients with treatment-resistant depression.
Read more
|
| |
|
Glycemic Control Improves with Motivational Texts |
For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.
Read more
|
